TY - JOUR
T1 - The effect of Am-80, a synthetic retinoid, on spinal cord injury-induced motor dysfunction in rats
AU - Takenaga, Mitsuko
AU - Ohta, Yuki
AU - Tokura, Yukie
AU - Hamaguchi, Akemi
AU - Shudo, Koichi
AU - Okano, Hideyuki
AU - Igarashi, Rie
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/2
Y1 - 2009/2
N2 - The present study investigated the effect of 4[(5,6,7,8-tetrahydro-5,5,8,8, -tetramethyl-2-naphthalenyl)car-bamoyl] benzoic acid (Am-80), a synthetic retinoid, on spinal cord injury (SCI) in rats. Treatment with Am-80 (orally and subcutaneously) significantly promoted recovery from SCI-induced motor dysfunction. On day 28 after injury, the lesion cavity was markedly reduced, while the expression of myelin basic protein (MBP; myelin), βIIItubulin (neuron), and glial fibrillary acidic protein (GFAP; astrocyte) was increased, in comparison with SCI controls. Interestingly, expression of neurotrophin receptor, tyrosine kinase B (TrkB) was over 3-fold higher after Am-80 treatment than in SCI controls. A lot of TrkB-positive cells as well as brain-derived neurotrophic factor (BDNF)-positive ones were observed around the injured site. Am-80 (10 μm) combined with BDNF (100ng/ml) promoted extensive neurite outgrowth and TrkB gene expression by cultured SH-SY5Y cells, as did all-trans retinoic acid (ATRA). Thymidine incorporation was dramatically suppressed, but there was little effect on cell viability. These findings suggest that Am-80 has the potential to be used for treating neurodegenerative disorders, including SCI. Its efficacy may be partly ascribed to promotion of cell viability and differentiation of neural stem cells through increased TrkB expression.
AB - The present study investigated the effect of 4[(5,6,7,8-tetrahydro-5,5,8,8, -tetramethyl-2-naphthalenyl)car-bamoyl] benzoic acid (Am-80), a synthetic retinoid, on spinal cord injury (SCI) in rats. Treatment with Am-80 (orally and subcutaneously) significantly promoted recovery from SCI-induced motor dysfunction. On day 28 after injury, the lesion cavity was markedly reduced, while the expression of myelin basic protein (MBP; myelin), βIIItubulin (neuron), and glial fibrillary acidic protein (GFAP; astrocyte) was increased, in comparison with SCI controls. Interestingly, expression of neurotrophin receptor, tyrosine kinase B (TrkB) was over 3-fold higher after Am-80 treatment than in SCI controls. A lot of TrkB-positive cells as well as brain-derived neurotrophic factor (BDNF)-positive ones were observed around the injured site. Am-80 (10 μm) combined with BDNF (100ng/ml) promoted extensive neurite outgrowth and TrkB gene expression by cultured SH-SY5Y cells, as did all-trans retinoic acid (ATRA). Thymidine incorporation was dramatically suppressed, but there was little effect on cell viability. These findings suggest that Am-80 has the potential to be used for treating neurodegenerative disorders, including SCI. Its efficacy may be partly ascribed to promotion of cell viability and differentiation of neural stem cells through increased TrkB expression.
KW - Am-80
KW - Neurotrophic factor
KW - Retinoid
KW - Spinal cord injury
UR - http://www.scopus.com/inward/record.url?scp=60749113185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60749113185&partnerID=8YFLogxK
U2 - 10.1248/bpb.32.225
DO - 10.1248/bpb.32.225
M3 - Article
C2 - 19182380
AN - SCOPUS:60749113185
SN - 0918-6158
VL - 32
SP - 225
EP - 231
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 2
ER -